Abstract
Saturation suppressor mutagenesis was used to generate thermostable mutants of the SARS-CoV-2 spike receptor-binding domain (RBD). A triple mutant with an increase in thermal melting temperature of ~7Ā°C with respect to the wild-type B.1 RBD and was expressed in high yield in both mammalian cells and the microbial host, Pichia pastoris, was downselected for immunogenicity studies. An additional derivative with three additional mutations from the B.1.351 (beta) isolate was also introduced into this background. Lyophilized proteins were resistant to high-temperature exposure and could be stored for over a month at 37Ā°C. In mice and hamsters, squalene-in-water emulsion (SWE) adjuvanted formulations of the B.1-stabilized RBD were considerably more immunogenic than RBD lacking the stabilizing mutations and elicited antibodies that neutralized all four current variants of concern with similar neutralization titers. However, sera from mice immunized with the stabilized B.1.351 derivative showed significantly decreased neutralization titers exclusively against the B.1.617.2 (delta) VOC. A cocktail comprising stabilized B.1 and B.1.351 RBDs elicited antibodies with qualitatively improved neutralization titers and breadth relative to those immunized solely with either immunogen. Immunized hamsters were protected from high-dose viral challenge. Such vaccine formulations can be rapidly and cheaply produced, lack extraneous tags or additional components, and can be stored at room temperature. They are a useful modality to combat COVID-19, especially in remote and low-resource settings.
Highlights
SARS-CoV-2 is the etiological agent of the ongoing pandemic which has so far resulted in over four million deaths worldwide [1]
A schematic of the principle of second-site saturation suppressor mutagenesis (SSSM) to isolate stabilizing mutations is shown in Figures 1AāD; more detailed descriptions can be found in Sahoo et al and Ahmed et al [32, 33]
These mutants were stable to incubation for 2 h at 60Ā°C and for up to 20 h at 50Ā° C, showing superior thermal tolerance to the WT (Supplementary Figure S1). mRBD1-3.3 had an exposed mutation V367F which is found in some circulating SARSCoV-2 virus isolates [44]
Summary
SARS-CoV-2 is the etiological agent of the ongoing pandemic which has so far resulted in over four million deaths worldwide [1]. The trimeric spike glycoprotein is the major surface protein of SARS-CoV-2 and the principal target of neutralizing antibodies [2]. The immunogens currently in clinical use or clinical trials are derived from the wildtype (WT) sequence [21] and employ the full-length viral spike as the primary antigen. Current VOC are B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta). Both B.1.351 and B.1.617.2 show substantially decreased neutralization by many existing monoclonal antibodies and by convalescent as well as vaccine sera [22,23,24]. We recently showed that both monomeric and intermolecular disulfide-linked, trimeric RBD derivatives were highly thermotolerant with the latter showing improved immunogenicity [28], albeit with significant antibody titers against the trimerization domain
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.